|September 30, 2010
Masur Auditorium on the NIH Campus
Building 10, Clinical Center
Lisa H. Butterfield, PhD ~ University of Pittsburgh
Mary L. (Nora) Disis, MD ~ University of Washington
Samir N. Khleif, MD ~ National Cancer Institute (CCR)
Francesco Marincola, MD ~ National Institutes of Health (CC, DTM)
To view slides from a presenter click on the icon
Nearly 230 attendees from academia, government and industry, representing 20 countries, convened at the NIH to interact with leading scientists and to listen to presentations on the latest information on immuno-oncology biomarkers.
Bernard A. Fox, PhD (Earle A. Chiles Research Institute) presented briefly on a collaborative effort with other domestic and international organizations to identify critical hurdles to cancer immunotherapy. The collaborating organizations are preparing a joint publication that defines these hurdles and offers solutions to accelerate the translation of cancer immunotherapy. More information on this collaborative effort is available online.
Samir N. Khleif, MD (National Cancer Institute, Center for Cancer Research) spoke briefly on the priorities in biomarker development in immunotherapy, while Lisa H. Butterfield, PhD (University of Pittsburgh) summarized work completed by the SITC/iSBTc Biomarkers Taskforce, which included the recent preparation of the position paper Recommendations from the iSBTc/FDA/NCI Workshop on Immunotherapy Biomarkers accepted for publication in Clinical Cancer Research.
Symposium faculty included 18 prominent scientists, who presented lectures on the topics below:
Speakers were joined by six panelists who represented other organizations for interactive discussions of these four areas, which are central to biomarker discovery, characterization and application in cancer immunotherapy.